Clinical Trials Logo

Clinical Trial Summary

A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia


Clinical Trial Description

CNGB3 retinal gene therapy for patients with achromatopsia ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03001310
Study type Interventional
Source MeiraGTx UK II Ltd
Contact
Status Completed
Phase Phase 1/Phase 2
Start date January 16, 2017
Completion date October 25, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04124185 - Natural History Study for Achromatopsia
Recruiting NCT02610582 - Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia Phase 1/Phase 2
Recruiting NCT02935517 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia Phase 1/Phase 2
Recruiting NCT03278873 - Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT01846052 - Clinical and Genetic Characterization of Individuals With Achromatopsia N/A
Active, not recruiting NCT01648452 - CNTF Implants for CNGB3 Achromatopsia Phase 1/Phase 2
Completed NCT03758404 - Gene Therapy for Achromatopsia (CNGA3) Phase 1/Phase 2
Recruiting NCT02599922 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia Phase 1/Phase 2
Not yet recruiting NCT04041232 - PBA Use for Treatment of ATF6-/- Patients Early Phase 1